Story perspectives

FDA Allows Mifepristone Access Amid Ongoing Legal Challenges

4/14/2026

Summary

Story summary

U.S. Food and Drug Administration (FDA) allowed dispensing in 2023, but U.S. pharmacies fill mifepristone prescriptions by mail.
A University of Southern California study finds that in telehealth states, fewer than 2% are filled at pharmacies.
Since the 2022 ruling, medication abortions account for 60% of U.S. abortions.
A federal judge temporarily halted Louisiana's lawsuit to limit mifepristone access.
Senate Republicans are investigating mifepristone manufacturers and urging FDA to curb sales.

1 of 1

Story summary

U.S. Food and Drug Administration (FDA) allowed dispensing in 2023, but U.S. pharmacies fill mifepristone prescriptions by mail.
A University of Southern California study finds that in telehealth states, fewer than 2% are filled at pharmacies.
Since the 2022 ruling, medication abortions account for 60% of U.S. abortions.
A federal judge temporarily halted Louisiana's lawsuit to limit mifepristone access.
Senate Republicans are investigating mifepristone manufacturers and urging FDA to curb sales.